Stryker said it has made a strategic equity investment of approximately $400 million in CMR Surgical.
The deal includes an exclusive option for Stryker to acquire the remaining equity of CMR Surgical, and an exclusive U.S. commercial agency agreement for the Versius portfolio.
The agreement brings together CMR Surgical’s soft-tissue robotics portfolio with Stryker’s scale and customer relationships. CMR Surgical will continue to lead portfolio development and commercialization in markets outside the United States.
Designed for real-world operating environments, the Versius platform’s modular architecture supports flexibility across procedures, surgeon access and sites of care, and can help healthcare providers grow robotic adoption within existing operating room workflows.
“Soft-tissue robotics is a high-growth adjacency and a natural extension of Stryker’s strengths in endoscopy, visualization and enabling technologies. We have evaluated the segment carefully for years, and this alliance represents a thoughtful and disciplined entry that combines the complementary strengths of both companies,” said Andy Pierce, group president for Medsurg and Neurotechnology at Stryker. “We selected CMR Surgical and the Versius portfolio because of the opportunity to help healthcare providers grow robotic-assisted surgery adoption across a broad range of procedures in hospitals and ASCs.”
“This strategic alliance is a significant milestone for CMR and a strong endorsement of the technology, clinical experience and global business we have built,” said CMR Surgical CEO Massimiliano Colella in a statement. “Stryker’s investment will give us additional strength to accelerate innovation and the continued global expansion of the Versius portfolio, while its scale and deep customer relationships create a significant growth opportunity in the United States. We also look forward to welcoming Andy Pierce to our board of directors and benefiting from his more than 30 years of MedTech leadership experience at Stryker as we continue expanding access to robotic-assisted surgery globally.”
